SecBot SecBot

LEGN

Legend Biotech Corp
Nasdaq· Pharmaceutical Preparations· Inc. E9· CIK 0001801198 Biotech & Drug Discovery
$20.39 +1.12 (+5.81%)
Oct 26 4:00 PM ET · prev $19.27
Market cap
$3.7B
Mid cap
Consensus
Buy
73% Buy or better · 22 analysts
Median target
$48.00
+135% · range $24.00–68.00
Next earnings
Nov 10
in 15 days
1 year
−36.5%
from $32.12 · Oct 27
30 days
+9.5%
from $18.62
52-week range
$16.65–36.28
−44% from high · low Feb 4
Avg volume 20D
2.01M
shares / day
Short interest
16.39M
≈8.4% of shares · +12.0%
Days to cover
7.1
at average volume
Insider net
−$481.2K
0 buyers · 4 sellers · 12 mo
New fund stakes
3
Q2 2026 13F · 0 exits
SecBot read BULLISH 8 reports · 90 days
Balance 0 bearish · 5 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 4/8 ·Next Earnings date, Nov 10, 2026
Strongest BULLISH Legend Biotech announced preliminary Q3 2026 net trade sales of approximately $710 million for CARVYKTI, its…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    4 insiders sold $481.2K.

  • InstitutionsMIXED

    Q2 2026: 31 added (3 new), 22 trimmed or exited. Largest new: Assenagon Asset Management S.A $55.3M, Driehaus Capital Management $33.5M.

  • AnalystsBULLISH

    16 of 22 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest +12.0% to 16.39M shares. 7.1 days to cover, ≈8.4% of shares.

  • TrendUPTREND

    4% above its 50-day average.

Who's buying

13F· Q2 2026
3
new positions
0
exits
$106.1M
in new stakes
FundMoveSharesValue
GOLDMAN SACHS GROUP INCDOUBLED3,662,315$105.8M
Assenagon Asset Management S.A.NEW1,915,056$55.3M
Artisan Partners Limited PartnershipTRIM1,559,441$45.0M
Capital International InvestorsDOUBLED1,420,654$41.0M
MORGAN STANLEYDOUBLED1,394,531$40.3M
DRIEHAUS CAPITAL MANAGEMENT LLCNEW1,158,808$33.5M
RENAISSANCE TECHNOLOGIES LLCADD1,000,200$28.9M
JPMORGAN CHASE & CODOUBLED766,364$22.5M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

22 analysts
Buy 73% rate it Buy or better
Strong Buy5Buy11Hold6Sell0Strong Sell0
12-month targets · 13 analysts

Price is below the lowest target. Median implies +135%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Oct 13, 2026Barclays
MAINTAIN
MAINTAINOverweight
Oct 9, 2026JP Morgan
MAINTAIN
MAINTAINNeutral
Oct 8, 2026RBC Capital
MAINTAIN
MAINTAINOutperform
Sep 30, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Sep 11, 2026Barclays
MAINTAIN
MAINTAINOverweight
Sep 4, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$481.2K
sold · 4 insiders
DateInsiderTypeValue
Sep 29, 2026
Sanders Corazon (Corsee) D.
Director
SELL$258.9K
Sep 24, 2026
Sanders Corazon (Corsee) D.
Director
AWARD20,986 sh
Sep 24, 2026
Ji Darren Xiaohui
Director
AWARD28,330 sh
Sep 24, 2026
Mao Li
Director
AWARD20,986 sh
Sep 24, 2026
Casey Patrick John
Director
AWARD20,986 sh
Sep 24, 2026
Heyman Tomas J.
Director
AWARD20,986 sh
Sep 24, 2026
Salovey Peter
Director
AWARD28,330 sh
Sep 21, 2026
Santos Carlos E
Chief Financial Officer
AWARD19,676 sh

Earnings setup

Estimates
Nov 10
reports in 15 days

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY-$0.01-$0.01–-$0.01+0.0%$1.4B
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Sep 30, 2026
16,387,267
shares short
+12.0%
vs prior settlement
7.1
days to cover
≈8.4%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 15, 2026 SEC
Legend Biotech announced FDA clearance of its IND application for LB2501, a first-in-class dual-targeting (CD19/CD20)…
6-K — Impact 5/10
Oct 13, 2026 SEC
Legend Biotech announced preliminary Q3 2026 net trade sales of approximately $710 million for CARVYKTI, its only…
6-K — Impact 6/10
Sep 29, 2026 SEC
Director Corazon (Corsee) D. Sanders filed a Form 144 notice to sell 13,685 ADSs valued at approximately $258,915. The…
144 — Impact 2/10
Sep 29, 2026 Insider
Sanders Corazon (Corsee) D. sold 27,370 shares
Director @ $9.46 ($258.9K)
Sep 25, 2026 Press
Legend Biotech presented five-year follow-up data from CARTITUDE-2 Cohort A at IMS 2026, showing 50% of patients…
Impact 5/10
Sep 25, 2026 FDA
Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion
Five-year overall survival rate was 69.2%, adding to growing long-term evidence supporting the curat
Sep 24, 2026 Insider
Sanders Corazon (Corsee) D. was granted 20,986 shares
Director
Sep 24, 2026 Insider
Ji Darren Xiaohui was granted 28,330 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 10, 2026
Earnings date
LEGN Q3 2026 Earnings Before Market Open — 2026-11-10
Recent
Sep 25, 2026
FDA
Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion
Five-year overall survival rate was 69.2%, adding to growing long-term evidence supporting the curative potential of CARVYKTI in earlier-line RRMM
Aug 11, 2026
Earnings
Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights
BRIDGEWATER, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy…
Aug 11, 2026
Earnings date
LEGN Q2 2026 Earnings Before Market Open — 2026-08-11
Jul 31, 2026
Short interest
Short Interest: LEGN up 29% to 18.1M shares
Settlement 2026-07-31 | Days to cover: 6.04 | ≈9.75% of shares outstanding (est.)
Jul 27, 2026
Leadership
Legend Biotech Announces CEO Transition
BRIDGEWATER, N.J., July 27, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global leader…

SecBot reports

19 filings · 8 press releases · 11 bullish · 2 bearish · 6 neutral
All LEGN filing & press-release reports (27)